The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders
Suven Life Sciences (Suven) announced that they secured patents in China (CN103443093) and South Africa (2013/01143, 2013/06328) to their New Chemical Entities (NCE’s) for CNS therapy through mechanism of action – H3 Inverse agonist and these patents are valid until 2031, 2030 and 2031 respectively.
The granted claims of the patent include the class of selective H3 ligands discovered by Suven and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders.
Suven also secured a patent for their NCE in Mexico (326651) and the granted claims of this patent include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD) and the patent is valid through 2030.
With these new patents, Suven has a total of 16 granted patents from China, 19 granted patents from Mexico and 22 granted patents from South Africa. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally” says Venkat Jasti, Chief Executive Officer, Suven.
Comments are closed.